arrow
M

Marie-Hélène Delfau-Larue

University Paris-Est Creteil and INSERM U955
H指数:51
被引数:9,144

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

诱导治疗结束时的循环肿瘤DNA优于常规细胞微小残留病,用于预测滤泡性淋巴瘤的早期进展:RELEVANCE随机试验的辅助研究

2026-09-290
OAAI
Large B-cell Lymphoma: The LYSA pragmatic guidelines

弥漫大B细胞淋巴瘤:LYSA实用性指南

2025-12-030
OAAI
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study

Brentuximab Vedotin联合Gemcitabine治疗复发或难治性外周T细胞淋巴瘤:一项LYSA II期研究

2025-08-060
OAAI
Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model

阿扎胞苷在患者来源的异种移植滤泡辅助T细胞淋巴瘤模型中诱导p53介导的凋亡

LEUKEMIA
IF13.4
2025-05-200
OAAI
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study

靶向治疗克服了类型#2慢性淋巴细胞白血病的较差预后:一项真实世界多中心研究

LEUKEMIA
IF13.4
2025-04-010
OA
Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

p16的异常细胞质表达是接受一线阿糖胞苷为基础的免疫化疗的年轻MCL患者的一个新的强预后标志物,一项来自Lysa Group、Nordic Lymphoma Group和European MCL Network的研究

BLOOD
IF23.1
2024-11-050
PRE
Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
2022-08-0127
OAAI
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
2022-06-1634
OAAI
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
2021-10-011
OAAI
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
2021-01-2251
OA
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
2020-11-0116
OAAI
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
2020-07-1616
OAAI
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by theLYSAgroup
2020-06-257
PREAI
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
2020-04-0342
OAAI
Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay
2019-09-0527
OAAI